UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): APRIL 7, 2004 VASO ACTIVE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-31925 02-0670926 (State or other jurisdiction (Commission File No.) (IRS Employer of incorporation No.) Identification No.) 99 ROSEWOOD DRIVE, SUITE 260, DANVERS, MASSACHUSETTS 01923 (Address of principal executive offices including zip code) (978) 750-1991 (Registrant's telephone number, including area code) TABLE OF CONTENTS ITEM 5. OTHER EVENTS ITEM 7. EXHIBITS SIGNATURE EXHIBIT 99.1 - PRESS RELEASE ISSUED APRIL 7, 2004. ITEM 5. OTHER EVENTS On April 7, 2004, Vaso Active Pharmaceuticals, Inc. issued the press release attached to this Form 8-K as Exhibit 99.1. ITEM 7. EXHIBITS (c) EXHIBITS. Exhibit 99.1 - Press Release issued April 7, 2004. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VASO ACTIVE PHARMACEUTICALS, INC. By: /s/ John J. Masiz --------------------------- Name: John J. Masiz Title: President, CEO Date: April 7, 2004